Table 1 Comparison of clinical data between CRRT group and non-CRRT group [M(Q1,Q3)]

From: Development and validation of a predictive model for continuous renal replacement therapy in sepsis patients using the MIMIC-IV database

Variables

Total (n = 5013)

Non-CRRT group (n = 4488)

CRRT group (n = 525)

p

Hypertensive, n (%)

0.025

 No

2879 (57)

2553 (57)

326 (62)

 

 Yes

2134 (43)

1935 (43)

199 (38)

 

Congestive heart failure, n (%)

< 0.001

 No

4130 (82)

3728 (83)

402 (77)

 

 Yes

883 (18)

760 (17)

123 (23)

 

Chronic pulmonary disease, n (%)

1

 No

4065 (81)

3639 (81)

426 (81)

 

 Yes

948 (19)

849 (19)

99 (19)

 

Diabetes, n (%)

0.816

 No

3911 (78)

3504 (78)

407 (78)

 

 Yes

1102 (22)

984 (22)

118 (22)

 

Renal disease, n (%)

< 0.001

 No

4566 (91)

4147 (92)

419 (80)

 

 Yes

447 (9)

341 (8)

106 (20)

 

Severe liver disease, n (%)

< 0.001

 No

4308 (86)

3980 (89)

328 (62)

 

 Yes

705 (14)

508 (11)

197 (38)

 

Gender, n (%)

0.292

 Feman

1838 (37)

1634 (36)

204 (39)

 

 Man

3175 (63)

2854 (64)

321 (61)

 

Aki stage, n (%)

< 0.001

 No

967 (19)

967 (22)

0 (0)

 

 1

932 (19)

930 (21)

2 (0)

 

 2

1788 (36)

1788 (40)

0 (0)

 

 3

1326 (26)

803 (18)

523 (100)

 

Los hospital, median (Q1, Q3)

10.65 (5.76, 20.04)

9.94 (5.67, 18.48)

20.93 (9.95, 36.09)

< 0.001

Admission age, median (Q1, Q3)

50.21 (40.3, 55.81)

50.41 (40.31, 55.87)

49.09 (39.9, 55.33)

0.243

Los icu, median (Q1, Q3)

4.05 (2.08, 9.13)

3.71 (1.97, 7.87)

11.64 (5.11, 19.88)

< 0.001

Sofa score, median (Q1, Q3)

3 (2, 5)

3 (2, 4)

6 (4, 9)

< 0.001

Sbp, median (Q1, Q3)

118 (104, 134)

118 (104, 135)

113 (98, 131)

< 0.001

Mbp, median (Q1, Q3)

82 (72, 94)

83 (72, 95)

79 (68, 91)

< 0.001

Resp rate, median (Q1, Q3)

19 (16, 24)

19 (15, 24)

22 (18, 27)

< 0.001

spo2, median (Q1, Q3)

99 (96, 100)

99 (96, 100)

97 (93, 100)

< 0.001

inr, median (Q1, Q3)

1.3 (1.2, 1.6)

1.3 (1.1, 1.5)

1.6 (1.3, 2.4)

< 0.001

pt, median (Q1, Q3)

14.5 (12.8, 17.4)

14.3 (12.7, 16.8)

17.8 (14.1, 25.9)

< 0.001

ptt, median (Q1, Q3)

30.8 (26.9, 38)

30.3 (26.7, 36.4)

39.6 (31.1, 52.8)

< 0.001

Aniongap, median (Q1, Q3)

14 (11, 17)

14 (11, 17)

18 (15, 23)

< 0.001

Bicarbonate, median (Q1, Q3)

22 (19, 25)

22 (19, 25)

19 (15, 23)

< 0.001

Bun, median (Q1, Q3)

16 (12, 26)

16 (11, 23)

31 (19, 53)

< 0.001

Creatinine, median (Q1, Q3)

1 (0.7, 1.4)

0.9 (0.7, 1.3)

2.2 (1.4, 3.9)

< 0.001

Glucose, median (Q1, Q3)

128 (106, 167)

128 (106.75, 165)

133 (103, 194)

0.141

rbc, median (Q1, Q3)

3.62 (3.04, 4.24)

3.66 (3.08, 4.25)

3.29 (2.6, 4.07)

< 0.001

wbc, median (Q1, Q3)

12.7 (8.7, 17.5)

12.6 (8.8, 17.4)

13.6 (8.2, 19.3)

0.048

Hemoglobin, median (Q1, Q3)

10.8 (9.1, 12.7)

10.9 (9.3, 12.7)

10 (8.2, 12.1)

< 0.001

Lactate, median (Q1, Q3)

1.8 (1.2, 2.9)

1.7 (1.2, 2.6)

2.8 (1.7, 5.6)

< 0.001

ph, median (Q1, Q3)

7.36 (7.29, 7.42)

7.37 (7.3, 7.42)

7.3 (7.2, 7.38)

< 0.001

Platelet, median (Q1, Q3)

180 (124, 248)

184 (129, 252)

137 (86, 214)

< 0.001

apsiii, median (Q1, Q3)

46 (32, 66)

43 (31, 60)

82 (65, 99)

< 0.001

Weight, median (Q1, Q3)

85 (71.2, 100.9)

84 (70.6, 100)

93 (76, 111)

< 0.001

heart_rate, median (Q1, Q3)

93 (80, 108)

92 (80, 107)

100 (85, 117)

< 0.001

  1. Baseline clinical characteristics of patients receiving continuous renal replacement therapy (CRRT) versus those not receiving CRRT. Categorical variables are presented as counts (percentages), and continuous variables are expressed as medians with interquartile ranges [M (Q1, Q3)]. Statistically significant differences were observed in variables such as AKI stage, renal disease, severe liver disease, and ICU length of stay. P-values were calculated using the chi-square test for categorical variables and the Mann–Whitney U test for continuous variables.
Back to article page